Clinical trial · Observational
Awareness and Attitudes Regarding Prenatal and Preimplantation Genetic Diagnosis for Inherited Breast/Ovarian Cancer Risk
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
We are inviting you to participate in a study of how people who have had genetic counseling for breast/ovarian cancer risk feel about certain reproductive technologies, preimplantation genetic diagnosis (PGD) and prenatal genetic diagnosis (PND), that may reduce the chances of passing increased risk onto one's children. We would also like feedback from patients who have been to our clinic in the past on the best ways to talk about PGD and PND during genetic counseling sessions. We are seeking both the opinions of people who are interested in these technologies and those who are not. It does not matter whether you have heard of PGD or PND before - you can still participate. Your past experience with genetic counseling is valuable to us in deciding how to communicate this information during sessions.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| questionnaire, interview | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- 1
- description
- 25 female and 5 male BRCA carriers
- interventionNames
- Behavioral: questionnaire, interview
Primary outcomes (1)
- measure
- To explore the attitudes of BRCA1/2 mutation carriers about PGD/PND, most notably benefits and drawbacks, as well as ethical and emotional considerations;
- timeFrame
- conclusion of study
Secondary outcomes (3)
- measure
- To elicit opinions from patients who have previously undergone BRCA1/2 genetic counseling as to when and how information about PGD/PND should be presented (e.g., timing, level of detail,etc)
- timeFrame
- conclusion of study
- measure
- To explore whether different themes emerge for subgroups of patients (completed childbearing vs. not; affected vs. unaffected).
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 39 Years
Show eligibility criteria text
Inclusion Criteria: * Females and males who are carriers of deleterious mutations in the genes BRCA1 or BRCA2. * Over age 18 and: 1. For women, less than 43 2. For men, less than 50. * Received genetic testing and counseling for BRCA. * Fluent in English. Exclusion Criteria: * Patients who are currently under treatment (chemotherapy, radiation) * Individuals who refuse to discuss reproductive issues. * Unable to give informed consent due to physical, cognitive, or psychiatric disability
References
Publications (0)
Data not yet available